Brilacidin is under clinical development by Innovation Pharmaceuticals and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Brilacidin’s likelihood of approval (LoA) and phase transition for Chemotherapy Induced Oral Mucositis took place on 20 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Brilacidin Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Brilacidin overview

Brilacidin (PMX-30063) is under development for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by Staphylococcus aureus, including MRSA and MSSA, encephalitic alphaviruses, including venezuelan equine encephalitis virus (VEEV), eastern equine encephalitis virus (EEEV), and sindbis virus (SINV), chemotherapy induced oral mucositis in patients with head and neck cancer who have received chemoradiation, ulcerative proctosigmoiditis, monkeypox, ulcerative proctitis, hidradenitis suppurativa, acne and atopic dermatitis, coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and COVID-19 associated cytokine storm and inflammatory bowel disease. It is administered through intravenous route, rectal route, topical, ophthalmic, auricular as well as orally. Brilacidin is a defensin mimetic compound which works as a bacterial cell membrane disruptor. The drug candidate is developed based on CDDT (computational drug design) technology. It was also under development for bacterial keratitis, lung infections, bacterial conjunctivitis, otitis media, vancomycin-resistant Enterococcus infections, diabetic foot wounds, ulcers caused by infections, bone and joint infections.

Innovation Pharmaceuticals overview

Innovation Pharmaceuticals, formerly Cellceutix, is a biopharmaceutical company that discovers and advances medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications. The company provides pipeline products such as kevetrin for the treatment of advanced solid tumors and acute myelogenous leukemia, among others. Innovation Pharmaceuticals offers pipeline products such as Brilacidin for the treatment of oral mucositis and skin infections; and Prurisol for the treatment of psoriasis. It works in collaboration with various research institutions across the US and other European countries. Innovation Pharmaceuticals is headquartered in Beverly, Massachusetts, the US.

Quick View Brilacidin LOA Data

Report Segments
  • Innovator
Drug Name
  • Brilacidin
Administration Pathway
  • Auricular (Otic)
  • Intravenous
  • Ophthalmic
  • Oral
  • Rectal
  • Topical
Therapeutic Areas
  • Dermatology
  • Ear Nose Throat Disorders
  • Gastrointestinal
  • Infectious Disease
  • Metabolic Disorders
  • Musculoskeletal Disorders
  • Ophthalmology
  • Respiratory
  • Toxicology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.